Dr. Narasimhan, has over fifteen years of experience working with leading pharmaceutical and biotechnology companies and has extensive scientific and capital markets expertise . Dr. Narasimhan joined Allergan in December 2018 and most recently served as Senior Vice President of Strategic Initiatives, Portfolio Innovation and Investor Relations where she was ranked #1 by Institutional Investor for Best Investor Relations Professional, Best IR Team, and Best IR Program in the pharmaceuticals sector. Prior to joining Allergan, Dr. Narasimhan worked at Regeneron Pharmaceuticals (NASDAQ:REGN) from 2011 to 2018, where she led the investor relations group. Prior to joining Regeneron, Dr. Narasimhan was an equity research analyst covering biotechnology at Canaccord Genuity and at Piper Jaffray. Dr. Narasimhan began her career as a strategy consultant for pharmaceutical and biotechnology companies at Campbell Alliance Group Inc. . Dr. Narasimhan received her Ph.D. in molecular biology from New York University. Additionally, Dr. Narasimhan has served on the Board of Directors for Cytonus Therapeutics Inc, a privately held biotechnology company since March 2020.